PDC*line Pharma

PDC*line Pharma is a French-Belgian clinical-stage biotechnology company developing a novel class of active immunotherapies for cancer treatment. This cancer vaccine contains a proprietary, potent, and scalable plasmacytoid dendritic cell line (PDC*line) with superior characteristics that make it highly suitable for immunotherapy. The PDC*line demonstrates greater effectiveness in priming and boosting antitumor antigens, including neoantigens, specific cytotoxic T cells, and enhancing responses to checkpoint inhibitors compared to traditional vaccines.